PR Magnesium Sulfate Hydrate Injection 100mg (Magnesium Sulfate Hydrate)

Adult administration

For seizures due to hypomagnesemia: 1 to 2 g of magnesium sulfate should be administered intravenously (4.05 to 8.1 mmol). For eclampsia attacks: 4 to 5 g of this medication should be intravenously administered over 10 minutes (16.2 to 20.25 mmol). To prevent uterine contractions: 4 g of this medication should be administered intravenously initially (16.2 mmol). Afterward, an additional 1 g may be administered. Electrolyte replacement (hypomagnesemia):

Child administration

Children: The safety of this medication has not been tested.

Care must be taken when using glass ampoules to avoid contamination with glass fragments. This medication should be handled with extra caution when used in children or the elderly. This medication should not be used in patients with poor kidney function, unconscious patients, patients with high blood magnesium levels, patients with cardiac conduction disorders, and patients with myasthenia gravis. Caution is needed when administering this drug to children with intestinal parasitic infections and patients with heart disease. While using this medication, gastrointestinal symptoms such as vomiting and dry mouth may occur, and rare side effects such as cardiac rhythm abnormalities or vasodilation may also occur. Additionally, neurological symptoms such as headache, tremors, and tingling may appear. In case of overdose, symptoms may include fever and severe thirst, decreased blood pressure, and suppression of heart rate and respiration. In such cases, calcium preparations should be administered intravenously to provide antidote. This medication may potentiate the effects of central nervous system depressants, so caution is required. Moreover, it may interfere with the absorption of iron supplements, certain antibiotics, and fluoride compounds if used together. During pregnancy, this drug is especially used for the treatment of eclampsia but may cause muscle relaxation or respiratory depression in the fetus, so fetal heart rate must be closely monitored. It should be avoided during labor or immediately after delivery, and caution is necessary due to potential effects on fetal bone health with prolonged administration. Lactating women should avoid using this medication except in special cases, as its safety has not been sufficiently verified. Elderly patients may have reduced bodily functions, so it is essential to administer this drug slowly and reduce the dose carefully. In cases of overdose, increased blood magnesium levels may lead to dangerous symptoms such as cardiac conduction disorder, decreased reflex function, consciousness impairment, respiratory depression, and cardiac arrest. In such situations, administration should be immediately stopped and calcium gluconate injection should be provided as an antidote treatment. This medication should be injected slowly at a concentration of less than 10% when administered intravenously, and mixing with other medications should be avoided as precipitation may occur. Additionally, to prevent infection, the injection site must be thoroughly disinfected, opened medications should be used immediately, and any leftover medication should not be reused.

Serious side effects

Conduction disorders, bradycardia, respiratory paralysis due to magnesium toxicity

Mild side effects

• Vomiting
• dry mouth
• flushing
• peripheral vasodilation
• headache
• heaviness in the head
• tremors
• tingling
• feeling of warmth
• thirst

This drug must be stored in a sealed container to prevent air ingress, and the storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature. This ensures that the effectiveness and safety of the medication are well preserved.

Appearance

Colorless liquid in a colorless ampoule

Package unit

25 ampoules/box [5ml/ampoule]